Top

Published in:

01-12-2016 | Original Article

Clinical science workshop: targeting the gut-liver-brain axis

Authors: Vishal C. Patel, Helen White, Sidsel Støy, Jasmohan S. Bajaj, Debbie L. Shawcross

Published in: Metabolic Brain Disease | Issue 6/2016

Abstract

A clinical science workshop was held at the ISHEN meeting in London on Friday 11th September 2014 with the aim of thrashing out how we might translate what we know about the central role of the gut-liver-brain axis into targets which we can use in the treatment of hepatic encephalopathy (HE). This review summarises the integral role that inter-organ ammonia metabolism plays in the pathogenesis of HE with specific discussion of the roles that the small and large intestine, liver, brain, kidney and muscle assume in ammonia and glutamine metabolism. Most recently, the salivary and gut microbiome have been shown to underpin the pathophysiological changes which culminate in HE and patients with advanced cirrhosis present with enteric dysbiosis with small bowel bacterial overgrowth and translocation of bacteria and their products across a leaky gut epithelial barrier. Resident macrophages within the liver are able to sense bacterial degradation products initiating a pro-inflammatory response within the hepatic parenchyma and release of cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-8 into the systemic circulation. The endotoxemia and systemic inflammatory response that are generated predispose both to the development of infection as well as the manifestation of covert and overt HE. Co-morbidities such as diabetes and insulin resistance, which commonly accompany cirrhosis, may promote slow gut transit, promote bacterial overgrowth and increase glutaminase activity and may need to be acknowledged in HE risk stratification assessments and therapeutic regimens. Therapies are discussed which target ammonia production, utilisation or excretion at an individual organ level, or which reduce systemic inflammation and endotoxemia which are known to exacerbate the cerebral effects of ammonia in HE. The ideal therapeutic strategy would be to use an agent that can reduce hyperammonemia and reduce systemic inflammation or perhaps to adopt a combination of therapies that can address both.

Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK (2009) Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 136:2159–2168. doi:10.1053/j.gastro.2009.02.050 PubMedCrossRef

Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 107:1043–1050. doi:10.1038/ajg.2012.113 PubMedCrossRef

Ahboucha S, Pomier-Layrargues G, Mamer O, Butterworth RF (2006) Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. Neurochem Int 49:372–378. doi:10.1016/j.neuint.2006.02.002 PubMedCrossRef

Als-Nielsen B, Gluud LL, Gluud C (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328:1046. doi:10.1136/bmj.38048.506134.EE PubMedPubMedCentralCrossRef

Ampuero J et al (2012) Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One 7:e49279. doi:10.1371/journal.pone.0049279 PubMedPubMedCentralCrossRef

Bai G, Rama Rao KV, Murthy CR, Panickar KS, Jayakumar AR, Norenberg MD (2001) Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. J Neurosci Res 66:981–991PubMedCrossRef

Bajaj JS (2014) The role of microbiota in hepatic encephalopathy. Gut Microbes 5:397–403. doi:10.4161/gmic.28684 PubMedPubMedCentralCrossRef

Bajaj JS et al (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140:478–487. doi:10.1053/j.gastro.2010.08.061, e471 PubMedCrossRef

Bajaj JS et al (2012a) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303:G675–G685. doi:10.1152/ajpgi.00152.2012 PubMedPubMedCentralCrossRef

Bajaj JS et al (2012b) Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 302:G168–G175. doi:10.1152/ajpgi.00190.2011 PubMedCrossRef

Bajaj JS et al (2013) Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 8:e60042. doi:10.1371/journal.pone.0060042 PubMedPubMedCentralCrossRef

Bajaj JS et al (2014a) Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 39:1113–1125. doi:10.1111/apt.12695 PubMedPubMedCentralCrossRef

Bajaj JS et al (2014b) Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60:940–947. doi:10.1016/j.jhep.2013.12.019 PubMedCrossRef

Bajaj JS et al (2015) Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. doi:10.1002/hep.27819 PubMedCentral

Banares R et al (2013) Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 57:1153–1162. doi:10.1002/hep.26185 PubMedCrossRef

Banks WA, Ortiz L, Plotkin SR, Kastin AJ (1991) Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 259:988–996PubMed

Banks WA, Kastin AJ, Gutierrez EG (1994) Penetration of interleukin-6 across the murine blood–brain barrier. Neurosci Lett 179:53–56PubMedCrossRef

Baquero F, Nombela C (2012) The microbiome as a human organ. Clin Microbiol Infect 18(Suppl 4):2–4. doi:10.1111/j.1469-0691.2012.03916.x PubMedCrossRef

Bass NM et al (2010) Rifaximin treatment in hepatic encephalopathy. New Engl J Med 362:1071–1081PubMedCrossRef

Basu S, Zethelius B, Helmersson J, Berne C, Larsson A, Arnlov J (2011) Cytokine-mediated inflammation is independently associated with insulin sensitivity measured by the euglycemic insulin clamp in a community-based cohort of elderly men. Int J Clin Exp Med 4:164–168PubMedPubMedCentral

Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J (2007) Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 46:1844–1852. doi:10.1002/hep.21838 PubMedCrossRef

Berry PA et al (2011) Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. Intensive Care Med 37:453–460. doi:10.1007/s00134-010-2099-7 PubMedCrossRef

Blei AT, Cordoba J (2001) Practice parameters committee of the American College of G. Hepatic encephalopathy. Am J Gastroenterol 96:1968–1976. doi:10.1111/j.1572-0241.2001.03964.x PubMedCrossRef

Blei AT, Olafsson S, Therrien G, Butterworth RF (1994) Ammonia-induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology 19:1437–1444PubMedCrossRef

Bosoi CR, Rose CF (2009) Identifying the direct effects of ammonia on the brain. Metab Brain Dis 24:95–102. doi:10.1007/s11011-008-9112-7 PubMedCrossRef

Bosoi CR, Yang X, Huynh J, Parent-Robitaille C, Jiang W, Tremblay M, Rose CF (2012) Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure. Free Radic Biol Med 52:1228–1235. doi:10.1016/j.freeradbiomed.2012.01.006 PubMedCrossRef

Caly WR, Strauss E (1993) A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 18:353–358PubMedCrossRef

Cauli O, Rodrigo R, Piedrafita B, Boix J, Felipo V (2007) Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 46:514–519. doi:10.1002/hep.21734 PubMedCrossRef

Cauli O, Mansouri MT, Agusti A, Felipo V (2009) Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex. Gastroenterology 136(1359–1367):e1351–e1352. doi:10.1053/j.gastro.2008.12.057

Cenit MC, Matzaraki V, Tigchelaar EF, Zhernakova A (2014) Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta 1842:1981–1992. doi:10.1016/j.bbadis.2014.05.023 PubMedCrossRef

Chastre A, Jiang W, Desjardins P, Butterworth RF (2010) Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. Metab Brain Dis 25:17–21. doi:10.1007/s11011-010-9185-y PubMedCrossRef

Chen MF, Mo LR, Lin RC, Kuo JY, Chang KK, Liao C, Lu FJ (1997) Increase of resting levels of superoxide anion in the whole blood of patients with decompensated liver cirrhosis. Free Radic Biol Med 23:672–679PubMedCrossRef

Chen Y et al (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54:562–572. doi:10.1002/hep.24423 PubMedCrossRef

Cirera I et al (2001) Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 34:32–37PubMedCrossRef

Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P (1999) Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29:648–653. doi:10.1002/hep.510290309 PubMedCrossRef

Cordoba J et al (2001) The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 35:598–604PubMedCrossRef

Cordoba J et al (2004) Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 41:38–43. doi:10.1016/j.jhep.2004.03.023 PubMedCrossRef

Courson A, Jones GM, Twilla JD (2015) Treatment of acute hepatic encephalopathy: comparing the effects of adding rifaximin to lactulose on patient outcomes. J Pharm Pract. doi:10.1177/0897190014566312 PubMed

de Vos WM (2013) Fame and future of faecal transplantations--developing next-generation therapies with synthetic microbiomes. Microb Biotechnol 6:316–325. doi:10.1111/1751-7915.12047 PubMedPubMedCentralCrossRef

Erceg S, Monfort P, Cauli O, Montoliu C, Llansola M, Piedrafita B, Felipo V (2006) Role of extracellular cGMP and of hyperammonemia in the impairment of learning in rats with chronic hepatic failure. Therapeutic implications. Neurochem Int 48:441–446. doi:10.1016/j.neuint.2005.10.016 PubMedCrossRef

Felig P, Owen OE, Wahren J, Cahill GF Jr (1969) Amino acid metabolism during prolonged starvation. J Clin Invest 48:584–594. doi:10.1172/JCI106017 PubMedPubMedCentralCrossRef

Gluud LL et al (2013) Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 143:1263–1268. doi:10.3945/jn.113.174375 PubMedCrossRef

Gluud LL et al (2015) Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2:CD001939. doi:10.1002/14651858.CD001939.pub2

Guarner F, Malagelada JR (2003) Gut flora in health and disease. Lancet 361:512–519. doi:10.1016/S0140-6736(03)12489-0 PubMedCrossRef

Hassanein TI et al (2007) Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46:1853–1862. doi:10.1002/hep.21930 PubMedCrossRef

Haussinger D, Lamers WH, Moorman AF (1992) Hepatocyte heterogeneity in the metabolism of amino acids and ammonia. Enzyme 46:72–93PubMed

Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S (2000) Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 32:1035–1038PubMedCrossRef

Hermenegildo C, Montoliu C, Llansola M, Munoz MD, Gaztelu JM, Minana MD, Felipo V (1998) Chronic hyperammonemia impairs the glutamate-nitric oxide-cyclic GMP pathway in cerebellar neurons in culture and in the rat in vivo. Eur J Neurosci 10:3201–3209PubMedCrossRef

Hermenegildo C, Monfort P, Felipo V (2000) Activation of N-methyl-D-aspartate receptors in rat brain in vivo following acute ammonia intoxication: characterization by in vivo brain microdialysis. Hepatology 31:709–715. doi:10.1002/hep.510310322 PubMedCrossRef

Human Microbiome Project C (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207–214. doi:10.1038/nature11234 CrossRef

Jalan R, Kapoor D (2003) Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 52:1041–1045PubMedPubMedCentralCrossRef

Jalan R, Olde Damink SW, Hayes PC, Deutz NE, Lee A (2004) Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol 41:613–620. doi:10.1016/j.jhep.2004.06.011 PubMedCrossRef

Jalan R, Wright G, Davies NA, Hodges SJ (2007) L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 69:1064–1069. doi:10.1016/j.mehy.2006.12.061 PubMedCrossRef

Jiang W, Desjardins P, Butterworth RF (2009) Minocycline attenuates oxidative/nitrosative stress and cerebral complications of acute liver failure in rats. Neurochem Int 55:601–605. doi:10.1016/j.neuint.2009.06.001 PubMedCrossRef

Jiang W et al (2015) Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 5:8096. doi:10.1038/srep08096 PubMedPubMedCentralCrossRef

Jones EA (2003) Potential mechanisms of enhanced GABA-mediated inhibitory neurotransmission in liver failure. Neurochem Int 43:509–516PubMedCrossRef

Kawaguchi T, Izumi N, Charlton MR, Sata M (2011) Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 54:1063–1070. doi:10.1002/hep.24412 PubMedCrossRef

Kircheis G, Wettstein M, Dahl S, Haussinger D (2002) Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 17:453–462PubMedCrossRef

Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–230. doi:10.1038/nature11550 PubMedPubMedCentralCrossRef

Maffeo E, Montuschi A, Stura G, Giordana MT (2014) Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients. Neurol Sci 35:523–530. doi:10.1007/s10072-013-1458-x PubMedCrossRef

Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M (1996) Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 23:1084–1092. doi:10.1053/jhep.1996.v23.pm0008621138 PubMedCrossRef

Marchesini G et al (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124:1792–1801PubMedCrossRef

Martinez-Hernandez A, Bell KP, Norenberg MD (1977) Glutamine synthetase: glial localization in brain. Science 195:1356–1358PubMedCrossRef

McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev:CD008716 doi:10.1002/14651858.CD008716.pub2

Montoliu C et al (2011) 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol 106:1629–1637. doi:10.1038/ajg.2011.123 PubMedCrossRef

Morgan XC, Segata N, Huttenhower C (2013) Biodiversity and functional genomics in the human microbiome. Trends Genet 29:51–58. doi:10.1016/j.tig.2012.09.005 PubMedCrossRef

Muto Y et al (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 3:705–713

Nagaraja TN, Brookes N (1998) Intracellular acidification induced by passive and active transport of ammonium ions in astrocytes. Am J Physiol 274:C883–C891PubMed

Nava GM, Stappenbeck TS (2011) Diversity of the autochthonous colonic microbiota. Gut Microbes 2:99–104. doi:10.4161/gmic.2.2.15416 PubMedPubMedCentralCrossRef

Nolan JP (2010) The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 52:1829–1835. doi:10.1002/hep.23917 PubMedCrossRef

Odeh M, Sabo E, Srugo I, Oliven A (2005) Relationship between tumor necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med 37:603–612. doi:10.1080/07853890500317414 PubMedCrossRef

Olde Damink SW, Deutz NE, Dejong CH, Soeters PB, Jalan R (2002) Interorgan ammonia metabolism in liver failure. Neurochem Int 41:177–188PubMedCrossRef

Olde Damink SW et al (2003) The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 37:1277–1285. doi:10.1053/jhep.2003.50221 PubMedCrossRef

Ong JP et al (2003) Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 114:188–193PubMedCrossRef

Owyang C, Wu GD (2014) The gut microbiome in health and disease. Gastroenterology 146:1433–1436. doi:10.1053/j.gastro.2014.03.032 PubMedCrossRef

Patel V et al (2014) Rifaximin is efficacious in the treatment of chronic overt hepatic encephalopathy: a UK liver multi-centre experience. Gut 63(Suppl 1):A14–A15. doi:10.1136/gutjnl-2014-307263.29

Plauth M et al (1993) Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. J Hepatol 17:308–314PubMedCrossRef

Pomier-Layrargues G, Spahr L, Butterworth RF (1995) Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 345:735PubMedCrossRef

Poo JL et al (2006) Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 5:281–288PubMed

Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559. doi:10.1002/hep.21533 PubMedCrossRef

Qin J et al (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65. doi:10.1038/nature08821 PubMedPubMedCentralCrossRef

Qin N et al (2014) Alterations of the human gut microbiome in liver cirrhosis. Nature 513:59–64. doi:10.1038/nature13568 PubMedCrossRef

Quinlan GJ, Martin GS, Evans TW (2005) Albumin: biochemical properties and therapeutic potential. Hepatology 41:1211–1219. doi:10.1002/hep.20720 PubMedCrossRef

Qvartskhava N et al (2015) Hyperammonemia in gene-targeted mice lacking functional hepatic glutamine synthetase. Proc Natl Acad Sci U S A 112:5521–5526. doi:10.1073/pnas.1423968112 PubMedPubMedCentralCrossRef

Rahimi RS, Singal AG, Cuthbert JA, Rockey DC (2014) Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med 174:1727–1733. doi:10.1001/jamainternmed.2014.4746 PubMedCrossRef

Rockey DC et al (2014) Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 59:1073–1083. doi:10.1002/hep.26611 PubMedPubMedCentralCrossRef

Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R (2000) The systemic inflammatory response syndrome in acute liver failure. Hepatology 32:734–739. doi:10.1053/jhep.2000.17687 PubMedCrossRef

Romero LI, Tatro JB, Field JA, Reichlin S (1996) Roles of IL-1 and TNF-alpha in endotoxin-induced activation of nitric oxide synthase in cultured rat brain cells. Am J Physiol 270:R326–R332PubMed

Romero-Gomez M, Ramos-Guerrero R, Grande L, de Teran LC, Corpas R, Camacho I, Bautista JD (2004) Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 41:49–54. doi:10.1016/j.jhep.2004.03.021 PubMedCrossRef

Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF (1998) L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 13:147–157PubMedCrossRef

Sharma BC, Sharma P, Agrawal A, Sarin SK (2009) Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137:885–891. doi:10.1053/j.gastro.2009.05.056, 891 e881 PubMedCrossRef

Shawcross DL, Jalan R (2004) Treatment of hepatic encephalopathy: it’s not lactulose. BMJ 329:112. doi:10.1136/bmj.329.7457.112, author reply 112 PubMedPubMedCentralCrossRef

Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40:247–254PubMedCrossRef

Shawcross DL et al (2008) Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 48:1202–1212. doi:10.1002/hep.22474 PubMedCrossRef

Shawcross DL et al (2011) Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 54:640–649. doi:10.1016/j.jhep.2010.07.045 PubMedCrossRef

Shreiner AB, Kao JY, Young VB (2015) The gut microbiome in health and in disease. Curr Opin Gastroenterol 31:69–75. doi:10.1097/MOG.0000000000000139 PubMedPubMedCentralCrossRef

Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 106:307–316. doi:10.1038/ajg.2010.455 PubMedCrossRef

Simon-Talero M et al (2013) Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 59:1184–1192. doi:10.1016/j.jhep.2013.07.020 PubMedCrossRef

Singh R et al (2011) Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin Immunol 138:41–49. doi:10.1016/j.clim.2010.09.006 PubMedCrossRef

Smith PM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569–573. doi:10.1126/science.1241165 PubMedCrossRef

Sorensen M, Keiding S (2007) New findings on cerebral ammonia uptake in HE using functional (13)N-ammonia PET. Metab Brain Dis 22:277–284. doi:10.1007/s11011-007-9066-1 PubMedCrossRef

Stenbog P, Busk T, Larsen FS (2013) Efficacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange. Metab Brain Dis 28:333–335. doi:10.1007/s11011-013-9403-5 PubMedCrossRef

Streetz K et al (2000) Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 119:446–460PubMedCrossRef

Takada Y et al (2001) Increased intracranial pressure in a porcine model of fulminant hepatic failure using amatoxin and endotoxin. J Hepatol 34:825–831PubMedCrossRef

Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H (2010) Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther 32:1080–1090. doi:10.1111/j.1365-2036.2010.04448.x PubMedCrossRef

Taylor NJ et al (2013) Circulating neutrophil dysfunction in acute liver failure. Hepatology 57:1142–1152. doi:10.1002/hep.26102 PubMedCrossRef

Taylor NJ et al (2014) The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther 40:705–715. doi:10.1111/apt.12886 PubMedCrossRef

Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI (2007) The human microbiome project. Nature 449:804–810. doi:10.1038/nature06244 PubMedPubMedCentralCrossRef

Vaquero J et al (2003) Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 125:755–764. doi:10.1016/s0016-5085(03)01051-5 PubMedCrossRef

Ventura-Cots M et al (2013) Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study. J Clin Gastroenterol 47:881–887. doi:10.1097/MCG.0b013e318299c789 PubMedCrossRef

Vilstrup H et al (2014) Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the european association for the study of the liver. Hepatology 60:715–735. doi:10.1002/hep.27210 PubMedCrossRef

Wiest R, Garcia-Tsao G (2005) Bacterial translocation (BT) in cirrhosis. Hepatology 41:422–433. doi:10.1002/hep.20632 PubMedCrossRef

Wright G et al (2007a) Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 45:1517–1526. doi:10.1002/hep.21599 PubMedCrossRef

Wright G, Shawcross D, Olde Damink SW, Jalan R (2007b) Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 22:375–388. doi:10.1007/s11011-007-9071-4 PubMedCrossRef

Xu J, Ma R, Chen LF, Zhao LJ, Chen K, Zhang RB (2014) Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int: HBPD INT 13:354–360PubMedCrossRef

Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura SI, Watanabe A, Tsuji T (2001) Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 55:349–355PubMed

Ytrebo LM et al (2009) L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 50:165–174. doi:10.1002/hep.22917 PubMedCrossRef

Zemtsova I, Gorg B, Keitel V, Bidmon HJ, Schror K, Haussinger D (2011) Microglia activation in hepatic encephalopathy in rats and humans. Hepatology 54:204–215. doi:10.1002/hep.24326 PubMedCrossRef

Title: Clinical science workshop: targeting the gut-liver-brain axis
Authors: Vishal C. Patel
Helen White
Sidsel Støy
Jasmohan S. Bajaj
Debbie L. Shawcross
Publication date: 01-12-2016
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 6/2016
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-015-9743-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical science workshop: targeting the gut-liver-brain axis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Qualifying and quantifying minimal hepatic encephalopathy

Probiotics in management of hepatic encephalopathy

Brain edema: a valid endpoint for measuring hepatic encephalopathy?

What we know: the inflammatory basis of hepatic encephalopathy

No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt

Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE